uniQure Announces Preliminary Data on the First Cohort in the Phase I/IIa Clinical Trial of AMT-260 in Refractory Mesial Temporal Lobe EpilepsyAMT-260 has shown good tolerance overall, with no serious adverse effects reported so far, while also displaying initial signs of potential therapeutic efficacy.
